Dr. Kilian Huber (November 17th, 2017)
It was a pleasure to welcome Dr. Kilian Huber, Group Head at the Structural Genomics Consortium, Target Discovery Institute at the University of Oxford, to our institute in November 2017. His research focuses on development of small molecules for novel drug targets in cancer and inflammatory diseases. His seminar lecture was entitled “Chemical Probes for Drug Target Validation”. We thank Dr. Kilian Huber for his visit and time.
Prof. Rudolf Kirchmair (October 20th, 2017)
Prof. Rudolf Kirchmair from the Medical University in Innsbruck visited us on October 2017 and gave a talk about mouse models and their use to assess metabolic and vascular pathologies contributing to atherosclerosis. He is associate director at the Department for Internal Medicine III – Cardiology and Angiology at the Medical University in Innsbruck. He is an important collaboration partner within studies to assess drug-induced vasculopathies.
Dr. Sigurd Broesby-Olsen (September 22nd, 2017)
Dr. Sigurd Broesby-Olsen (MD) from the Mastocytosis Centre Odense University Hospital (MastOUH) in Denmark visited Prof. Valent and his research group on Friday, September 22nd in 2017. As part of the joint seminar of the SFB F47-B20 and the Ludwig Boltzmann Cluster Oncology Dr. Sigurd Broesby-Olsen talked about “Diagnostic algorithms in patients with suspected SM”. With MastOUH Dr. Sigurd Broesby-Olsen is an active member of the European Competence Network on Mastocytosis (ECNM).
Prof. Dr. Michael W. Deininger (October 8th, 2017)
Prof. Dr. Michael W. Deininger is Head of Hematology and Hematologic Malignancies at the Department of Internal Medicine at the University of Utah. His main interest is chronic myeloid leukemia (CML). He gained extensive experience treating patients suffering from CML at the University Hospital of Utah. In October 2017 he presented us very interesting data about TNF signaling in myeloproliferative neoplasms. Afterwards we had a fruitful discussion and some exchange about new ideas for possible upcoming studies in CML.
Prof. Dr. Daniel Wicklein (August 25th, 2017)
It was a pleasure to welcome Prof. Dr. Wicklein at the Medical University of Vienna. He is group leader at the Institute for Anatomy and Experimental Morphology at the University Medical Center Hamburg-Eppendorf. His main research focuses on metastasis formation in mouse models. At the seminar lecture he talked about models of dissemination and metastasis formation of human neoplastic cells in mice. After the talk, we could discuss about our experiences with in vivo experiments, such as engraftment of human cancer cells in various mouse models.
Dr. Chiara Elena & Prof. Dr. Luca Malcovati (May 12nd, 2017)
In May 2017, Dr. Chiara Elena and Prof. Dr. Luca Malcovati were visiting us from the University of Pavia in Italy. Both scientists are working at the Department of Hematology Oncology and the Department of Molecular Medicine. Prof. Dr. Luca Malcovati is Assistant Professor of Hematology and his primary area of clinical and research interest are the myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPN). Dr. Chiara Elena is also and hematologist and working in the field of MDS and MPN. Both are active members in clinical and translational research programs in MDS and MPN. The seminar lecture was entitled “Clinical implication of somatic mutations in myeloid neoplasms with myelodysplasia: MDS and CMML”. We thank both for their time to visit us and present recent data about their research work.
Dr. Thomas Köcher (April 14th, 2017)
Dr. Thomas Köcher, from the Vienna Biocenter Core Facilities (VBCF) visited us on April 2017. He talked about metabolomics in cancer research and beyond. He is Core Facility Head of Metabolomics and generates quantitative pictures of small biomolecules. He and his team offer analysis of extracts from various biological samples using targeted liquid chromatography-tandem mass spectroscopy (LC-MS/MS). He has more than 15 years experience in quantitative and qualitative Analytics. It was very interesting for us to get insights in the research field of metabolomics.
Dr. Georg Winter (February 17th, 2017)
Georg Winter is a principal inverstigator at the CeMM. In his seminar he presented a novel pharmacological concept how to target oncoproteins in cancer cells. Dr. Winter gave a very interesting talk about the development and mechanism of protein-degrading drugs and their effects on survival of AML and ALL cells including LSC.